SAN MARINO, Calif., June 15, 2011 /PRNewswire/ -- Viral Genetics, Inc., (Pinksheets: VRAL) is pleased to announce that Boston-based Research 2.0 today released an 8-page report focused on the Company's majority-owned subsidiary, VG Energy, Inc. The report is available on the company's website at www.viralgenetics.com/investors/research20_June2011.php and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.
Research 2.0 is pioneering a new "open professional" model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.
"As with any coverage like this we will let the report and analysts speak for themselves, but we are very pleased to see the exciting new developments at VG Energy get professionally analyzed, described and evaluated for all of our stakeholders," said Viral Genetics and VG Energy CEO, Haig Keledjian.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks a